



BRITISH COLUMBIA  
CENTRE *for* EXCELLENCE  
*in* HIV/AIDS

# B.C. HIV/AIDS Drug Treatment Program

Monthly Report

October 2023





© 2024 BC Centre for Excellence in HIV/AIDS

**DISCLAIMER:** This document is published by the British Columbia Centre for Excellence in HIV/AIDS (BC-CfE) as an overview of the activities of the BC-CfE's Drug Treatment Program. All information is generated from a live database maintained by the BC-CfE that houses data for clinical and virological outcome studies of patients receiving antiretroviral therapy.

This database is updated on a regular basis. Figures and tables provided in this Monthly Report represent the best estimates available at the time this document was generated.

Please be advised that information provided in this document is provided in good faith and is derived from sources believed to be accurate and up-to-date at the report's date of publication. The BC Centre for Excellence in HIV/AIDS nevertheless reserves the right to update this information at any time.

Information provided here at this time, is being provided freely, and no kind of agreement or contract is created between you and the authors. The authors cannot be responsible for any violations should you reproduce or republish the information contained herein.

Please note that the figures and graphs in this document are best viewed in colour.

### **BC Centre for Excellence in HIV/AIDS Drug Treatment Program**

St. Paul's Hospital  
687 - 1081 Burrard Street  
Vancouver, BC  
V6Z 1Y6

Tel: 604.806.8515  
Fax: 604.806.9044

Physician Drug Hotline: 1.800.665.7677  
St. Paul's Hospital Pharmacy Hotline: 1.888.511.6222  
Website: [www.bccfe.ca](http://www.bccfe.ca)  
Email: [info@bccfe.ca](mailto:info@bccfe.ca)

Funding for the BC Centre for Excellence in HIV/AIDS is provided through Pharmacare and the Provincial Health Services Authority (PHSA)





## EXECUTIVE SUMMARY

A key component of the BC Centre for Excellence in HIV/AIDS' (BC-CfE) mandate is to monitor the impact of HIV/AIDS in British Columbia. The BC-CfE provides essential information to local health authorities, treating physicians, and the community at large on an ongoing basis. The HIV/AIDS Drug Treatment Program (DTP) Update is one example of the BC-CfE's commitment to people living with HIV throughout the Province of British Columbia.

The DTP distributes anti-HIV drugs at no cost to eligible British Columbians. The DTP Update provides an important overview of available anti-HIV drugs, common drug combinations and distribution of active DTP participants throughout the province.

DTP participants are typically followed at three-monthly intervals at which time routine blood sampling is performed. Information from all recipients is entered into a database, providing data for clinical and virological outcome studies of patients receiving antiretroviral therapy. These studies form the basis of ongoing revisions to the BC-CfE's treatment guidelines.





### TABLE OF CONTENTS

#### 1. List of Figures

- 1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority
- 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants
- 1.5 BC-CfE Enrolment: New Antiretroviral Participants
- 1.6 Percent Distribution of Active Participants by CD4 Count
- 1.7 Percent Distribution of Inactive Participants by CD4 Count
- 1.8 Active and Inactive Participants
- 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by Ingredient
- 1.12 Distribution of Participants on Protease Inhibitor by Ingredient
- 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by Ingredient
- 1.14 Distribution of Participants on Non-Nucleosides by Ingredient
- 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by Ingredient
- 1.16 Distribution of Participants on Entry/Integrase Inhibitors by Ingredient
- 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first start of ARV Therapy by Ingredient
- 1.18 Baseline CD4 for Antiretroviral First Starts
- 1.19 DTP Participants with PVL Measurement within previous five years, and never on ART
- 1.20 Cumulative Resistance Testing Results by Resistance Category
- 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category

#### 2. List of Tables

- 2.1 Duration of ARV treatment in the Province of BC, 1987-2022 (for HIV+ persons currently on treatment)
- 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program
- 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program
- 2.4 BC-CfE Enrolment
- 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs
- 2.6 Number of Participants on Nucleoside/Nucleotide Analogues by Ingredient
- 2.7 Number of Participants on Protease Inhibitor by Ingredient
- 2.8 Number of Participants on Non-Nucleosides by Ingredient
- 2.9 Number of Participants on Entry/Integrase Inhibitors by Ingredient
- 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category
- 2.11 Baseline CD4 for Antiretroviral First Starts
- 2.12 DTP Participants with PVL Measurement within previous five years, and never on ART





## Table of Contents, cont'd...

### 3. Health Authority Maps

- 3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants
- 3.2 Interior Health Authority & Kelowna
- 3.3 Fraser Health Authority & Surrey
- 3.4 Vancouver Coastal Health Authority & Vancouver
- 3.5 Vancouver Island Health Authority & Victoria
- 3.6 Northern Health Authority & Prince George

### 4. Health Authority Tables

#### INTERIOR HEALTH

- 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.3 Distribution of ARV Prescribers in BC-CfE Registries

#### FRASER HEALTH

- 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.6 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER COASTAL

- 4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.9 Distribution of ARV Prescribers in BC-CfE Registries

#### VANCOUVER ISLAND

- 4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.12 Distribution of ARV Prescribers in BC-CfE Registries

#### NORTHERN HEALTH

- 4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at birth
- 4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration
- 4.15 Distribution of ARV Prescribers in BC-CfE Registries

#### ABORIGINAL

- 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at birth

### 5. Appendix

- 5.1 Drug Names and Definitions






1.1 Distribution of males and females on antiretroviral therapy in British Columbia by Health Authority

October 2023

N = 7621



Health Authority	Male	Female	All
FRASER	1534	474	2008
INTERIOR	464	121	585
NORTHERN	152	79	231
VANCOUVER COASTAL	3320	453	3773
VANCOUVER ISLAND	831	168	999
	<b>6301</b>	<b>1295</b>	<b>7596</b>
		<b>Unknown/not stated:</b>	<b>25</b>
		<b>Total:</b>	<b>7621</b>

Definitions:

On antiretroviral therapy defined as being on treatment in the current month


Unknown/not stated defined as being on treatment in the current month, and city of residence unknown

Male & Female refer to Sex at birth





### 1.2 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (October 2018 - October 2023)




**Notes:**

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





### 1.3 Percent Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category (October 2018 - October 2023)



**Notes:**


Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month








### 1.4 BC-CfE Enrolment: Net Number of New Antiretroviral Participants (October 2018 - October 2023)






### 1.5 BC-CfE Enrolment: New Antiretroviral Participants (October 2018 - October 2023)






1.6 Percent Distribution of Active Participants by CD4 Count  
(October 2018 - October 2023)






### 1.7 Percent Distribution of Inactive Participants by CD4 Count (October 2018 - October 2023)






1.8 Active and Inactive Participants  
(October 2018 - October 2023)






### 1.9 Percent Distribution of Participants on ARV Therapy by Number of Drugs (October 2018 - October 2023)






### 1.10 Distribution of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT (October 2018 - October 2023)





### 1.11 Distribution of Participants on Nucleoside/Nucleotide Analogues at the time of first start of ARV Therapy by INGREDIENT


(October 2018 - October 2023)








### 1.12 Distribution of Participants on Protease Inhibitor by INGREDIENT (October 2018 - October 2023)






### 1.13 Distribution of Participants on Protease Inhibitor at the time of first start of ARV Therapy by INGREDIENT

(October 2018 - October 2023)






### 1.14 Distribution of Participants on Non-Nucleosides by INGREDIENT (October 2018 - October 2023)






### 1.15 Distribution of Participants on Non-Nucleosides at the time of first start of ARV Therapy by INGREDIENT

(October 2018 - October 2023)






### 1.16 Distribution of Participants on Entry/Integrase Inhibitors by INGREDIENT (October 2018 - October 2023)






### 1.17 Distribution of Participants on Entry/Integrase Inhibitors at the time of first ARV Therapy by INGREDIENT

(October 2018 - October 2023)






1.18 Baseline CD4 for Antiretroviral First Starts (October 2018 - October 2023)






1.19 DTP Participants with PVL Measurement within previous five years, and never on ART (October 2018 - October 2023)








### 1.20 Cumulative Resistance Testing Results by Resistance Category (October 2018 - October 2023)





### 1.21 Percent of Participants ever on ARV - Resistance Testing Results by Resistance Category (October 2018 - October 2023)





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
1987	32	4	0	4	1	980	3	<40	4
1988	32	4	0	4	1	420	4	<40	4
1989	30	50	1	51	17	520	44	<40	3
1990	29	49	1	50	25	550	48	<40	3
1991	29	36	3	39	16	570	37	<40	3
1992	29	48	5	53	20	605	51	<40	3
1993	28	113	15	128	66	550	120	<40	3
1994	27	65	12	77	39	580	72	<40	3
1995	27	117	19	136	73	530	126	<40	3
1996	25	291	45	336	173	570	311	<40	3
1997	22	261	30	291	149	570	265	<40	3
1998	22	175	40	215	117	570	188	<40	3
1999	22	141	38	179	99	570	158	<40	3
2000	22	112	27	139	80	615	120	<40	3
2001	21	107	25	132	69	620	114	<40	3
2002	20	114	23	137	82	565	128	<40	3
2003	20	134	26	160	103	630	147	<40	3
2004	19	136	37	173	103	630	159	<40	3
2005	18	166	38	204	129	690	190	<40	3
2006	17	162	38	200	108	660	174	<40	3
2007	16	224	44	268	158	665	246	<40	3
2008	15	259	58	317	195	660	283	<40	3
2009	14	288	65	353	201	620	316	<40	3
2010	13	243	66	309	177	680	281	<40	3
2011	12	310	69	379	224	700	335	<40	3
2012	11	257	64	321	185	660	292	<40	3
2013	10	246	63	309	174	685	280	<40	3
2014	9	259	45	304	160	740	271	<40	3
2015	8	255	44	299	165	690	263	<40	3
2016	7	233	50	283	156	680	245	<40	3
2017	6	195	29	224	127	700	195	<40	3
2018	5	170	45	215	125	770	191	<40	3

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





**2.1 Duration of ARV treatment in the Province of BC, 1987-2023  
(for HIV+ persons currently on treatment)**

Start Year	Duration (years) Median	Male	Female	All	Current CD4 (n)	Median	Current PVL (n)	Median	Current ARV Median
2019	4	219	40	259	162	670	230	<40	3
2020	3	164	52	216	141	730	187	<40	3
2021	2	179	34	213	133	610	196	<40	3
2022	1	253	46	299	194	685	278	<40	3
2023	0	256	57	313	264	550	303	<40	3
<b>Total:</b>		<b>6295</b>	<b>1294</b>	<b>7589</b>					

**Definitions:**

**On treatment** defined as being on ARV therapy in the specified month and not reported deceased

**Duration** defined as cumulative years on ARV therapy, excluding periods of treatment interruption

**Current CD4 and PVL tests** defined as tests done in the last 6 months (most recent)

**Current ARV** defined as number of ARV drugs in the current regimen





## 2.2 Median Viral Load and CD4 for Active patients in Drug Treatment Program

MON-YYYY	# of patients	Median # of therapy days	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	7465	756	1878	<40	1317	650
FEB-2022	7386	774	1803	<40	1263	620
MAR-2022	7458	766	1904	<40	1251	620
APR-2022	7420	778	1755	<40	1153	620
MAY-2022	7477	763	1998	<40	1306	620
JUN-2022	7482	759	1839	<40	1201	630
JUL-2022	7495	754	1761	<40	1141	645
AUG-2022	7492	758	1990	<40	1227	620
SEP-2022	7442	772	1787	<40	1092	636
OCT-2022	7468	778	1849	<40	1164	640
NOV-2022	7502	783	1898	<40	1202	630
DEC-2022	7544	787	1607	<40	1005	640
JAN-2023	7581	793	2051	<40	1318	650
FEB-2023	7521	807	1727	<40	1017	630
MAR-2023	7548	803	1973	<40	1214	640
APR-2023	7553	796	1761	<40	1082	630
MAY-2023	7592	786	1932	<40	1230	650
JUN-2023	7599	787	1841	<40	1091	630
JUL-2023	7577	806	1747	<40	1050	620
AUG-2023	7605	805	1814	<40	1023	630
SEP-2023	7620	796	1775	<40	1049	650
OCT-2023	7621	803	1888	<40	1121	620

**Definitions:**

**Active patient** defined as being on ARV treatment in the specified month

**Therapy days** defined as number of consecutive days on ARV treatment (most recent uninterrupted period)

**PVL and CD4 tests** defined as tests done in the specified month





### 2.3 Median Viral Load and CD4 for Inactive patients in Drug Treatment Program

MON-YYYY	# of patients	Median # days of off therapy	# of patients with PVL test	Median PVL	# of patients with CD4 test	Median CD4
JAN-2022	786	273	55	<40	45	580
FEB-2022	856	232	73	<40	56	635
MAR-2022	800	285	94	<40	73	480
APR-2022	834	278	70	<40	53	550
MAY-2022	758	317	60	<40	43	490
JUN-2022	761	291	61	<40	43	400
JUL-2022	764	283	61	<50	36	447
AUG-2022	787	261	59	78	49	560
SEP-2022	844	209	71	<40	53	460
OCT-2022	822	210	83	<40	62	495
NOV-2022	808	207	80	50	60	505
DEC-2022	773	230	57	<40	45	560
JAN-2023	734	276	63	<40	45	550
FEB-2023	787	230	66	<40	53	550
MAR-2023	756	242	78	<40	56	512
APR-2023	762	218	66	<40	47	560
MAY-2023	728	240	65	<40	48	430
JUN-2023	711	204	57	<40	39	460
JUL-2023	742	186	68	<40	50	565
AUG-2023	741	192	63	<40	39	590
SEP-2023	727	209	55	<40	41	540
OCT-2023	736	215	59	<40	43	600

**Definitions:**

**Inactive patient** defined as not deceased, not being on ARV treatment in the specified month (but previously treated with ARVs), and had contact with program in past 5 years

**Days off therapy** defined as number of days elapsed since last ARV treatment

**PVL and CD4 tests** defined as tests done in the specified month





2.4 BC-CfE Enrolment

MON-YYYY	Currently on ARV Therapy	Currently off ARV Therapy	Deceased	First Starts	Experienced Starts	New Inactive	Net Change	Cumulative Patients
JAN-2022	7432	786	19	7	161	144	2	14485
FEB-2022	7371	856	8	9	151	211	-61	14510
MAR-2022	7432	800	16	9	232	160	61	14539
APR-2022	7397	834	11	1	156	178	-35	14559
MAY-2022	7450	758	13	13	205	146	53	14583
JUN-2022	7457	761	11	15	178	170	7	14620
JUL-2022	7469	764	10	13	188	176	12	14659
AUG-2022	7468	787	15	17	169	172	-1	14697
SEP-2022	7423	845	13	15	146	192	-46	14725
OCT-2022	7443	822	14	16	195	171	20	14760
NOV-2022	7480	808	9	17	210	177	37	14799
DEC-2022	7511	773	19	8	213	167	31	14826
JAN-2023	7550	734	20	10	192	143	39	14861
FEB-2023	7505	787	10	11	158	204	-45	14885
MAR-2023	7532	756	15	21	197	176	27	14919
APR-2023	7531	762	13	11	176	169	-1	14948
MAY-2023	7575	728	7	15	205	165	44	14992
JUN-2023	7578	711	14	17	168	165	3	15027
JUL-2023	7558	742	11	12	163	181	-20	15058
AUG-2023	7582	741	11	15	215	192	24	15103
SEP-2023	7587	727	14	6	179	162	5	15124
OCT-2023	7589	736	17	10	172	161	2	15154

**Definitions:**

**Currently on ARV Therapy** defined as being on ARV treatment in the specified month, and not deceased/moved out of BC

**Currently off ARV Therapy** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARVs in the past

**Deceased** defined as deceased in the specified month, and being on ARV treatment in the previous month

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Experienced Starts** defined as starting ARV treatment in the specified month, but previously being treated with ARVs

**New Inactive** defined as not being on ARV treatment in the specified month, not deceased/moved out of BC, but on ARV treatment in the previous month, and had contact with the program in the past 5 years

**Net Change** is defined as difference between ARV starts (First and Experienced) and ARV stops (Deceased/Moved out of BC and New Inactive)





### 2.5 Percent Distribution of Participants on ARV Therapy by Number of Drugs

MON-YYYY	Less than 3 Drugs	3 Drugs	4 Drugs	5 or more Drugs	All ARV	Less than 3 Drugs%	3 Drugs%	4 Drugs%	5 or more Drugs%	Total%
JAN-2022	499	6468	455	43	<b>7465</b>	6.68%	86.64%	6.10%	0.58%	<b>100.00%</b>
FEB-2022	525	6371	445	45	<b>7386</b>	7.11%	86.26%	6.02%	0.61%	<b>100.00%</b>
MAR-2022	550	6408	455	45	<b>7458</b>	7.37%	85.92%	6.10%	0.60%	<b>100.00%</b>
APR-2022	567	6357	450	46	<b>7420</b>	7.64%	85.67%	6.06%	0.62%	<b>100.00%</b>
MAY-2022	597	6381	452	47	<b>7477</b>	7.98%	85.34%	6.05%	0.63%	<b>100.00%</b>
JUN-2022	614	6376	450	42	<b>7482</b>	8.21%	85.22%	6.01%	0.56%	<b>100.00%</b>
JUL-2022	634	6371	445	45	<b>7495</b>	8.46%	85.00%	5.94%	0.60%	<b>100.00%</b>
AUG-2022	643	6364	442	43	<b>7492</b>	8.58%	84.94%	5.90%	0.57%	<b>100.00%</b>
SEP-2022	663	6295	439	45	<b>7442</b>	8.91%	84.59%	5.90%	0.60%	<b>100.00%</b>
OCT-2022	679	6309	439	41	<b>7468</b>	9.09%	84.48%	5.88%	0.55%	<b>100.00%</b>
NOV-2022	696	6318	447	41	<b>7502</b>	9.28%	84.22%	5.96%	0.55%	<b>100.00%</b>
DEC-2022	709	6344	450	41	<b>7544</b>	9.40%	84.09%	5.97%	0.54%	<b>100.00%</b>
JAN-2023	721	6371	445	44	<b>7581</b>	9.51%	84.04%	5.87%	0.58%	<b>100.00%</b>
FEB-2023	735	6318	429	39	<b>7521</b>	9.77%	84.00%	5.70%	0.52%	<b>100.00%</b>
MAR-2023	750	6312	445	41	<b>7548</b>	9.94%	83.62%	5.90%	0.54%	<b>100.00%</b>
APR-2023	765	6307	440	41	<b>7553</b>	10.13%	83.50%	5.83%	0.54%	<b>100.00%</b>
MAY-2023	801	6315	435	41	<b>7592</b>	10.55%	83.18%	5.73%	0.54%	<b>100.00%</b>
JUN-2023	820	6300	438	41	<b>7599</b>	10.79%	82.91%	5.76%	0.54%	<b>100.00%</b>
JUL-2023	844	6253	440	40	<b>7577</b>	11.14%	82.53%	5.81%	0.53%	<b>100.00%</b>
AUG-2023	866	6245	448	46	<b>7605</b>	11.39%	82.12%	5.89%	0.60%	<b>100.00%</b>
SEP-2023	881	6259	434	46	<b>7620</b>	11.56%	82.14%	5.70%	0.60%	<b>100.00%</b>
OCT-2023	900	6248	432	41	<b>7621</b>	11.81%	81.98%	5.67%	0.54%	<b>100.00%</b>

**Definitions:**

**Number of Drugs** is calculated as number of individual drugs in ARV Therapy (excluding low dose ritonavir used for boosting a protease inhibitor)







Monthly Report

**2.6 Number of Participants on Nucleoside/Nucleotide Analogues by INGREDIENT**

	lamivudine		abacavir		zidovudine		tenofovir <TAF>		tenofovir <TDF>		emtricitabine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	3 20%	3064 42%	3 20%	2480 34%	0 0%	19 0%	12 80%	2922 40%	0 0%	1473 20%	12 80%	4262 58%
FEB-2022	6 24%	3019 42%	3 12%	2410 33%	2 8%	19 0%	15 60%	2939 41%	4 16%	1395 19%	19 76%	4225 58%
MAR-2022	3 10%	3034 41%	2 7%	2406 33%	0 0%	19 0%	24 83%	3029 41%	2 7%	1350 18%	26 90%	4272 58%
APR-2022	4 20%	3019 41%	3 15%	2366 33%	0 0%	19 0%	14 70%	3052 42%	2 10%	1313 18%	16 80%	4250 58%
MAY-2022	4 17%	3026 41%	3 13%	2354 32%	0 0%	18 0%	17 74%	3145 43%	2 9%	1282 17%	19 83%	4309 59%
JUN-2022	5 14%	3015 41%	0 0%	2309 31%	0 0%	19 0%	29 81%	3199 44%	4 11%	1237 17%	31 86%	4320 59%
JUL-2022	4 10%	3007 41%	3 8%	2285 31%	0 0%	19 0%	27 69%	3229 44%	9 23%	1218 17%	35 90%	4343 59%
AUG-2022	5 14%	2991 41%	4 11%	2261 31%	0 0%	18 0%	29 78%	3271 45%	3 8%	1178 16%	32 86%	4354 59%
SEP-2022	4 14%	2952 40%	3 11%	2195 30%	0 0%	17 0%	19 68%	3284 45%	5 18%	1173 16%	24 86%	4352 60%
OCT-2022	6 17%	2950 40%	4 11%	2173 30%	0 0%	16 0%	29 83%	3350 46%	0 0%	1143 16%	29 83%	4388 60%
NOV-2022	7 18%	2948 40%	5 13%	2158 29%	0 0%	15 0%	26 68%	3387 46%	6 16%	1136 15%	31 82%	4417 60%
DEC-2022	4 15%	2951 40%	3 11%	2148 29%	1 4%	16 0%	18 67%	3446 47%	5 19%	1109 15%	23 85%	4445 60%
JAN-2023	6 17%	2971 40%	1 3%	2147 29%	1 3%	16 0%	23 66%	3491 47%	8 23%	1095 15%	29 83%	4465 60%
FEB-2023	3 13%	2944 40%	1 4%	2097 28%	0 0%	17 0%	18 75%	3502 47%	3 13%	1065 14%	21 88%	4446 60%
MAR-2023	2 6%	2936 40%	2 6%	2071 28%	0 0%	15 0%	27 79%	3551 48%	5 15%	1051 14%	32 94%	4476 60%
APR-2023	3 10%	2948 40%	1 3%	2067 28%	0 0%	15 0%	24 83%	3550 48%	3 10%	1030 14%	26 90%	4469 60%
MAY-2023	10 24%	2940 39%	4 10%	2043 27%	1 2%	16 0%	30 71%	3598 48%	3 7%	1040 14%	32 76%	4513 61%
JUN-2023	4 12%	2934 39%	1 3%	2008 27%	0 0%	14 0%	26 76%	3655 49%	4 12%	1002 13%	30 88%	4533 61%
JUL-2023	5 16%	2917 39%	1 3%	1966 26%	0 0%	14 0%	25 81%	3678 49%	2 6%	985 13%	26 84%	4530 61%
AUG-2023	4 9%	2911 39%	1 2%	1937 26%	0 0%	14 0%	34 76%	3719 50%	9 20%	969 13%	41 91%	4563 61%
SEP-2023	2 10%	2905 39%	1 5%	1913 26%	0 0%	13 0%	16 76%	3752 50%	3 14%	955 13%	19 90%	4585 61%
OCT-2023	2 7%	2906 39%	1 3%	1896 25%	0 0%	14 0%	22 73%	3772 50%	6 20%	938 13%	28 93%	4581 61%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS





**2.7 Number of Participants on Protease Inhibitor by INGREDIENT**

	fosamprenavir		atazanavir		darunavir		lopinavir		ritonavir		tipranavir	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	1 0%	0 0%	476 29%	0 0%	1132 68%	0 0%	60 4%	0 0%	1 0%	0 0%	1 0%
FEB-2022	0 0%	1 0%	1 33%	447 28%	1 33%	1110 69%	1 33%	60 4%	0 0%	1 0%	0 0%	1 0%
MAR-2022	0 0%	1 0%	0 0%	430 27%	2 100%	1113 70%	0 0%	57 4%	0 0%	1 0%	0 0%	1 0%
APR-2022	0 0%	1 0%	0 0%	424 27%	0 0%	1085 69%	0 0%	56 4%	0 0%	1 0%	0 0%	1 0%
MAY-2022	0 0%	1 0%	1 33%	417 27%	2 67%	1080 70%	0 0%	53 3%	0 0%	1 0%	0 0%	1 0%
JUN-2022	0 0%	1 0%	0 0%	407 27%	1 100%	1056 70%	0 0%	52 3%	0 0%	1 0%	0 0%	1 0%
JUL-2022	0 0%	1 0%	0 0%	405 27%	1 100%	1039 70%	0 0%	50 3%	0 0%	1 0%	0 0%	1 0%
AUG-2022	0 0%	1 0%	0 0%	385 26%	1 100%	1028 71%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
SEP-2022	0 0%	0 0%	0 0%	367 26%	2 100%	1010 71%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
OCT-2022	0 0%	0 0%	0 0%	354 25%	0 0%	1002 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
NOV-2022	0 0%	0 0%	0 0%	352 25%	6 100%	995 72%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
DEC-2022	0 0%	0 0%	0 0%	342 25%	1 100%	1008 72%	0 0%	45 3%	0 0%	1 0%	0 0%	1 0%
JAN-2023	0 0%	0 0%	0 0%	339 25%	1 100%	993 72%	0 0%	44 3%	0 0%	1 0%	0 0%	1 0%
FEB-2023	0 0%	0 0%	0 0%	321 24%	0 0%	953 73%	0 0%	43 3%	0 0%	1 0%	0 0%	1 0%
MAR-2023	0 0%	0 0%	0 0%	317 24%	1 100%	952 73%	0 0%	42 3%	0 0%	1 0%	0 0%	1 0%
APR-2023	0 0%	0 0%	0 0%	305 23%	1 100%	957 74%	0 0%	41 3%	0 0%	1 0%	0 0%	1 0%
MAY-2023	0 0%	0 0%	0 0%	304 24%	2 100%	951 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUN-2023	0 0%	0 0%	0 0%	295 23%	0 0%	936 74%	0 0%	39 3%	0 0%	1 0%	0 0%	1 0%
JUL-2023	0 0%	0 0%	0 0%	283 23%	3 100%	927 74%	0 0%	38 3%	0 0%	1 0%	0 0%	1 0%
AUG-2023	0 0%	0 0%	0 0%	276 23%	3 100%	914 75%	0 0%	37 3%	0 0%	0 0%	0 0%	0 0%
SEP-2023	0 0%	0 0%	1 100%	272 22%	0 0%	911 75%	0 0%	36 3%	0 0%	0 0%	0 0%	0 0%
OCT-2023	0 0%	0 0%	0 0%	273 23%	1 100%	892 75%	0 0%	35 3%	0 0%	0 0%	0 0%	0 0%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Ritonavir - greater than 400 mg total daily dose





**2.8 Number of Participants on Non-Nucleosides by INGREDIENT**

	doravirine		efavirenz		etravirine		nevirapine		rilpivirine	
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All
JAN-2022	0 0%	103 9%	0 0%	328 30%	0 0%	130 12%	0 0%	317 29%	0 0%	235 21%
FEB-2022	0 0%	106 10%	0 0%	317 29%	0 0%	127 12%	0 0%	306 28%	1 100%	228 21%
MAR-2022	0 0%	113 11%	1 100%	303 28%	0 0%	132 12%	0 0%	301 28%	0 0%	222 21%
APR-2022	1 50%	124 12%	1 50%	301 28%	0 0%	130 12%	0 0%	297 28%	0 0%	223 21%
MAY-2022	0 0%	136 13%	0 0%	287 27%	0 0%	128 12%	0 0%	290 27%	1 100%	220 21%
JUN-2022	1 33%	149 14%	1 33%	284 27%	0 0%	122 12%	0 0%	285 27%	1 33%	211 20%
JUL-2022	0 0%	155 15%	1 33%	280 27%	0 0%	117 11%	0 0%	280 27%	2 67%	207 20%
AUG-2022	0 0%	157 15%	1 33%	275 27%	0 0%	119 12%	0 0%	274 27%	2 67%	204 20%
SEP-2022	0 0%	167 16%	3 100%	271 27%	0 0%	110 11%	0 0%	273 27%	0 0%	200 20%
OCT-2022	0 0%	173 17%	0 0%	261 26%	0 0%	105 10%	0 0%	269 27%	0 0%	196 20%
NOV-2022	1 33%	182 18%	2 67%	261 26%	0 0%	108 11%	0 0%	269 27%	0 0%	197 19%
DEC-2022	0 0%	185 18%	1 25%	254 25%	0 0%	107 11%	1 25%	262 26%	2 50%	195 19%
JAN-2023	3 43%	192 19%	4 57%	247 25%	0 0%	107 11%	0 0%	255 26%	0 0%	191 19%
FEB-2023	0 0%	202 20%	0 0%	250 25%	0 0%	98 10%	0 0%	249 25%	0 0%	190 19%
MAR-2023	0 0%	209 21%	0 0%	242 25%	0 0%	101 10%	0 0%	246 25%	0 0%	186 19%
APR-2023	1 50%	215 22%	1 50%	232 24%	0 0%	96 10%	0 0%	245 25%	0 0%	187 19%
MAY-2023	1 33%	223 23%	0 0%	232 24%	0 0%	98 10%	0 0%	239 24%	2 67%	187 19%
JUN-2023	0 0%	224 23%	3 75%	228 24%	0 0%	96 10%	0 0%	230 24%	1 25%	180 19%
JUL-2023	0 0%	235 25%	1 100%	222 23%	0 0%	94 10%	0 0%	225 24%	0 0%	178 19%
AUG-2023	0 0%	238 25%	2 100%	222 23%	0 0%	92 10%	0 0%	223 23%	0 0%	182 19%
SEP-2023	0 0%	236 25%	0 0%	218 23%	0 0%	89 9%	1 100%	220 23%	0 0%	177 19%
OCT-2023	0 0%	239 26%	2 100%	217 23%	0 0%	89 10%	0 0%	220 24%	0 0%	173 19%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Doravirine not currently available on BC-CfE Formulary





**2.9 Number of Participants on Entry/Integrase Inhibitors by INGREDIENT**

	bictegravir		cabotegravir		dolutegravir		elvitegravir		fostemsavir		maraviroc		raltegravir															
	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All	Initial	All														
JAN-2022	11	73%	2421	43%	0	0%	0	0%	2	13%	2468	44%	1	7%	347	6%	0	0%	1	0%	0	0%	24	0%	1	7%	374	7%
FEB-2022	15	71%	2443	44%	0	0%	0	0%	6	29%	2437	44%	0	0%	331	6%	0	0%	1	0%	0	0%	21	0%	0	0%	369	7%
MAR-2022	23	85%	2536	45%	0	0%	0	0%	3	11%	2460	43%	1	4%	324	6%	0	0%	1	0%	0	0%	21	0%	0	0%	370	7%
APR-2022	14	74%	2574	45%	0	0%	0	0%	5	26%	2436	43%	0	0%	312	5%	0	0%	1	0%	0	0%	20	0%	0	0%	366	6%
MAY-2022	17	77%	2666	46%	0	0%	0	0%	5	23%	2455	43%	0	0%	309	5%	0	0%	1	0%	0	0%	22	0%	0	0%	360	6%
JUN-2022	29	85%	2710	47%	0	0%	0	0%	5	15%	2454	42%	0	0%	300	5%	0	0%	1	0%	0	0%	22	0%	0	0%	352	6%
JUL-2022	24	69%	2745	47%	0	0%	0	0%	7	20%	2452	42%	3	9%	297	5%	0	0%	1	0%	0	0%	22	0%	1	3%	342	6%
AUG-2022	26	76%	2790	48%	0	0%	0	0%	6	18%	2452	42%	1	3%	294	5%	0	0%	1	0%	1	3%	22	0%	1	3%	340	6%
SEP-2022	19	76%	2820	48%	0	0%	0	0%	6	24%	2433	42%	0	0%	281	5%	0	0%	1	0%	0	0%	21	0%	0	0%	323	6%
OCT-2022	28	80%	2889	49%	0	0%	0	0%	6	17%	2440	41%	1	3%	280	5%	0	0%	1	0%	0	0%	22	0%	0	0%	314	5%
NOV-2022	24	73%	2920	49%	0	0%	0	0%	8	24%	2462	41%	1	3%	276	5%	0	0%	2	0%	0	0%	22	0%	0	0%	309	5%
DEC-2022	16	70%	2974	50%	0	0%	0	0%	5	22%	2464	41%	1	4%	270	4%	0	0%	2	0%	0	0%	20	0%	1	4%	307	5%
JAN-2023	23	82%	3016	50%	0	0%	0	0%	5	18%	2492	41%	0	0%	269	4%	0	0%	2	0%	0	0%	21	0%	0	0%	302	5%
FEB-2023	18	75%	3040	50%	0	0%	0	0%	6	25%	2476	41%	0	0%	255	4%	0	0%	2	0%	0	0%	21	0%	0	0%	288	5%
MAR-2023	25	74%	3084	51%	0	0%	0	0%	5	15%	2482	41%	2	6%	259	4%	0	0%	2	0%	0	0%	20	0%	2	6%	291	5%
APR-2023	22	81%	3084	50%	0	0%	0	0%	4	15%	2498	41%	1	4%	258	4%	0	0%	2	0%	0	0%	18	0%	0	0%	274	4%
MAY-2023	28	67%	3138	51%	1	2%	3	0%	12	29%	2504	41%	1	2%	250	4%	0	0%	2	0%	0	0%	18	0%	0	0%	278	5%
JUN-2023	26	81%	3197	51%	0	0%	5	0%	6	19%	2509	40%	0	0%	248	4%	0	0%	2	0%	0	0%	18	0%	0	0%	267	4%
JUL-2023	25	83%	3218	52%	0	0%	5	0%	5	17%	2499	40%	0	0%	247	4%	0	0%	2	0%	0	0%	18	0%	0	0%	256	4%
AUG-2023	33	79%	3260	52%	0	0%	7	0%	6	14%	2497	40%	1	2%	245	4%	0	0%	2	0%	0	0%	18	0%	2	5%	254	4%
SEP-2023	15	75%	3294	52%	0	0%	8	0%	5	25%	2504	40%	0	0%	238	4%	0	0%	2	0%	0	0%	18	0%	0	0%	250	4%
OCT-2023	22	79%	3304	52%	0	0%	7	0%	6	21%	2527	40%	0	0%	241	4%	0	0%	2	0%	0	0%	18	0%	0	0%	248	4%

**Definitions:**

**Initial** is defined as number of patients whose first ARV treatment with the BC-CfE DTP contains INGREDIENT;

% is calculated as ratio of "Initial" and number of patients whose first treatment is of given CLASS

**All** is defined as number of patients on ARV treatment which contains INGREDIENT;

% is calculated as ratio of "All" and number of patients whose treatment is of given CLASS

Fostemsavir not currently on BC-CfE Formulary





### 2.10 Distribution of Participants in HIV/AIDS Drug Treatment Program by Regimen Category

MON-YYYY	Boosted PI + 2 N(t)RTIs		NNRTI + 2 N(t)RTIs		INSTI + 2 N(t)RTIs		2 drugs from 2 classes		IV 3 drugs from IV 3 classes		Other	
	n	%	n	%	n	%	n	%	n	%	n	%
JAN-2022	985	13.19	773	10.35	4452	59.64	496	6.64	674	9.03	85	1.14
FEB-2022	958	12.97	750	10.15	4409	59.69	522	7.07	668	9.04	79	1.07
MAR-2022	934	12.52	737	9.88	4482	60.10	548	7.35	674	9.04	83	1.11
APR-2022	908	12.24	725	9.77	4473	60.28	565	7.61	670	9.03	79	1.06
MAY-2022	898	12.01	709	9.48	4527	60.55	595	7.96	669	8.95	79	1.06
JUN-2022	873	11.67	705	9.42	4558	60.92	612	8.18	659	8.81	75	1.00
JUL-2022	857	11.43	698	9.31	4578	61.08	632	8.43	655	8.74	75	1.00
AUG-2022	827	11.04	691	9.22	4610	61.53	641	8.56	649	8.66	74	0.99
SEP-2022	799	10.74	691	9.29	4575	61.48	662	8.90	642	8.63	73	0.98
OCT-2022	788	10.55	673	9.01	4620	61.86	678	9.08	637	8.53	72	0.96
NOV-2022	770	10.26	682	9.09	4639	61.84	694	9.25	646	8.61	71	0.95
DEC-2022	774	10.26	663	8.79	4680	62.04	706	9.36	651	8.63	70	0.93
JAN-2023	750	9.89	665	8.77	4728	62.37	718	9.47	649	8.56	71	0.94
FEB-2023	715	9.51	665	8.84	4712	62.65	733	9.75	626	8.32	70	0.93
MAR-2023	699	9.26	653	8.65	4735	62.73	748	9.91	644	8.53	69	0.91
APR-2023	704	9.32	653	8.65	4736	62.70	762	10.09	634	8.39	64	0.85
MAY-2023	707	9.31	644	8.48	4752	62.59	799	10.52	627	8.26	63	0.83
JUN-2023	676	8.90	625	8.22	4788	63.01	818	10.76	627	8.25	65	0.86
JUL-2023	662	8.74	626	8.26	4758	62.80	842	11.11	628	8.29	61	0.81
AUG-2023	643	8.45	621	8.17	4777	62.81	864	11.36	633	8.32	67	0.88
SEP-2023	640	8.40	616	8.08	4800	62.99	879	11.54	620	8.14	65	0.85
OCT-2023	613	8.04	613	8.04	4819	63.23	897	11.77	617	8.10	62	0.81

**Definitions:**

n is number of participants on the specified regimen class in the specified month

% is ratio of n and total number of participants on ART in the specified month

Regimen categories may contain a small number of participants with undetermined regimen, due to medication change(s) within the month





**2.11 Baseline CD4 for Antiretroviral First Starts**

MON-YYYY	# of First Starts	# of Pts with CD4 < 100	# of Pts with CD4: 100-199	# of Pts with CD4: 200-349	# of Pts with CD4: 350-500	# of Pts with CD4 > 500	Median CD4
JAN-2022	7	1	0	1	1	3	490
FEB-2022	9	0	1	0	1	5	530
MAR-2022	9	4	1	1	1	2	150
APR-2022	1	0	0	0	0	1	820
MAY-2022	13	4	1	1	1	6	490
JUN-2022	15	1	4	1	4	4	400
JUL-2022	13	1	4	3	2	2	225
AUG-2022	17	1	3	3	2	5	330
SEP-2022	15	1	0	3	6	4	405
OCT-2022	16	0	0	1	5	9	520
NOV-2022	17	1	2	2	5	6	445
DEC-2022	8	1	1	2	0	1	320
JAN-2023	10	2	2	2	2	2	285
FEB-2023	11	2	2	3	1	3	253
MAR-2023	21	0	0	4	3	11	530
APR-2023	11	1	3	1	1	4	325
MAY-2023	15	2	1	2	5	2	374
JUN-2023	17	2	4	3	2	6	340
JUL-2023	12	1	2	4	2	3	265
AUG-2023	15	2	1	4	2	3	258
SEP-2023	6	1	1	0	0	3	616
OCT-2023	10	0	1	3	2	3	390

**Definitions:**

**First Starts** defined as starting ARV treatment in the specified month for the first time (ARV naive)

**Baseline CD4** is defined as most recent CD4 test before ARV start





**2.12 DTP Participants with PVL Measurement within previous five years, and never on ART**

MON-YYYY	# of Participants with PVL test	# of Participants with PVL test, and never on ART
JAN-2022	12277	3734
FEB-2022	12300	3748
MAR-2022	12328	3763
APR-2022	12357	3788
MAY-2022	12348	3777
JUN-2022	12363	3779
JUL-2022	12389	3788
AUG-2022	12410	3800
SEP-2022	12429	3809
OCT-2022	12455	3829
NOV-2022	12463	3819
DEC-2022	12440	3801
JAN-2023	12448	3803
FEB-2023	12436	3788
MAR-2023	12443	3787
APR-2023	12418	3753
MAY-2023	12426	3731
JUN-2023	12399	3693
JUL-2023	12426	3716
AUG-2023	12423	3698
SEP-2023	12410	3685
OCT-2023	12395	3662

**Definitions:**

**Patients with PVL test** are defined as having at least one PVL test within previous five years, and not reported deceased/moved


**Never on ART** are subset of patients with PVL test, and not being treated with ARVs on or before specified month






3.1 Distribution of HIV/AIDS Drug Treatment Program Active Participants N = 7621  
Oct-2023

BY HEALTH SERVICES DELIVERY AREA



BY HEALTH AUTHORITY









3.2 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Oct-2023

INTERIOR HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




KELOWNA BY POSTAL CODE






3.3 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Oct-2023

FRASER HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




SURREY BY POSTAL CODE






3.4 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Oct-2023

VANCOUVER COASTAL HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VANCOUVER BY POSTAL CODE






3.5 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Oct-2023

VANCOUVER ISLAND HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA




VICTORIA BY POSTAL CODE






3.6 Distribution of HIV/AIDS Drug Treatment Program Active Participant  
Oct-2023

NORTHERN HEALTH AUTHORITY BY HEALTH SERVICES DELIVERY AREA/LOCAL HEALTH AREA



PRINCE GEORGE BY POSTAL CODE





### 4.1 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth INTERIOR Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
EAST KOOTENAY	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>44</b>	<b>60</b>	<b>26</b>
KOOTENAY BOUNDARY	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>73</b>	<b>102</b>	<b>55</b>	
OKANAGAN	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>447</b>	<b>606</b>	<b>331</b>	
THOMPSON/CARIBOO/ SHUSWAP	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HSDA:</b>	<b>239</b>	<b>322</b>	<b>173</b>	
<b>Total HA:</b>		<b>803</b>	<b>1090</b>	<b>585</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>803</b>	<b>1090</b>	<b>585</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	162	221	121
Male	641	869	464

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	585	56	670	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





### 4.2 Distribution of Participants in BC-CfE Registries by Treatment Duration INTERIOR Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
EAST KOOTENAY	10 years or more	24	14
	5 years or more	14	7
	<5 years	6	5
	<b>Total HSDA:</b>	<b>44</b>	<b>26</b>
KOOTENAY BOUNDARY	10 years or more	48	34
	5 years or more	13	10
	<5 years	12	11
	<b>Total HSDA:</b>	<b>73</b>	<b>55</b>
OKANAGAN	10 years or more	281	205
	5 years or more	93	66
	<5 years	73	60
	<b>Total HSDA:</b>	<b>447</b>	<b>331</b>
THOMPSON/CARIBOO/ SHUSWAP	10 years or more	147	107
	5 years or more	46	30
	<5 years	46	36
	<b>Total HSDA:</b>	<b>239</b>	<b>173</b>
<b>Total HA:</b>		<b>803</b>	<b>585</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	500	360
5 years or more	166	113
<5 years	137	112
<b>Total HA:</b>	<b>803</b>	<b>585</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





### 4.3 Distribution of ARV Prescribers in BC-CfE Registries INTERIOR Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
EAST KOOTENAY	53	71	11	16
KOOTENAY BOUNDARY	76	138	19	42
OKANAGAN	241	1102	54	336
THOMPSON/CARIBOO/SHUSWAP	150	574	36	144
<b>Total:</b>	<b>520</b>	<b>1885</b>	<b>120</b>	<b>538</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
EAST KOOTENAY	13
KOOTENAY BOUNDARY	11
OKANAGAN	72
THOMPSON/CARIBOO/SHUSWAP	50
<b>Total:</b>	<b>146</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA







#### 4.4 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth FRASER Health Authority

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
FRASER EAST	0-19	7	7	6
	20-34	38	40	31
	35-49	101	104	68
	50+	270	377	205
	<b>Total HSDA:</b>		<b>416</b>	<b>528</b>
FRASER NORTH	20-34	140	141	101
	35-49	366	393	283
	50+	644	1029	486
	<b>Total HSDA:</b>		<b>1150</b>	<b>1563</b>
FRASER SOUTH	0-19	7	7	5
	20-34	119	121	87
	35-49	310	338	242
	50+	630	966	494
	<b>Total HSDA:</b>		<b>1066</b>	<b>1432</b>
<b>Total HA:</b>		<b>2632</b>	<b>3523</b>	<b>2008</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	14	14	11
	20-34	297	302	219
	35-49	777	835	593
	50+	1544	2372	1185
<b>Total HA:</b>		<b>2632</b>	<b>3523</b>	<b>2008</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	639	817	474
Male	1993	2706	1534

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	2008	53	655	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





#### 4.5 Distribution of Participants in BC-CfE Registries by Treatment Duration FRASER Health Authority

HSDA	Treatment Duration	Alive	Currently treated with ARVs
FRASER EAST	10 years or more	281	216
	5 years or more	67	41
	<5 years	68	53
	<b>Total HSDA:</b>	<b>416</b>	<b>310</b>
FRASER NORTH	10 years or more	721	525
	5 years or more	235	183
	<5 years	194	162
	<b>Total HSDA:</b>	<b>1150</b>	<b>870</b>
FRASER SOUTH	10 years or more	650	498
	5 years or more	215	160
	<5 years	201	170
	<b>Total HSDA:</b>	<b>1066</b>	<b>828</b>
<b>Total HA:</b>		<b>2632</b>	<b>2008</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	1652	1239
	5 years or more	517	384
	<5 years	463	385
<b>Total HA:</b>		<b>2632</b>	<b>2008</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





#### 4.6 Distribution of ARV Prescribers in BC-CfE Registries FRASER Health Authority

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
FRASER EAST	150	546	33	64
FRASER NORTH	262	1638	43	221
FRASER SOUTH	227	1829	45	491
<b>Total:</b>	<b>639</b>	<b>4013</b>	<b>121</b>	<b>776</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
FRASER EAST	206
FRASER NORTH	708
FRASER SOUTH	482
<b>Total:</b>	<b>1396</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.7 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
VANCOUVER COASTAL Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>355</b>	<b>529</b>
RICHMOND	20-34	30	31	20
	35-49	56	57	45
	50+	124	181	102
	<b>Total HSDA:</b>	<b>210</b>	<b>269</b>	<b>167</b>
VANCOUVER	0-19	12	12	10
	20-34	449	463	300
	35-49	1223	1365	880
	50+	2999	5381	2141
	<b>Total HSDA:</b>	<b>4683</b>	<b>7221</b>	<b>3331</b>
<b>Total HA:</b>		<b>5248</b>	<b>8019</b>	<b>3773</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	13	13	11
	20-34	507	522	336
	35-49	1351	1501	980
	50+	3377	5983	2446
<b>Total HA:</b>		<b>5248</b>	<b>8019</b>	<b>3773</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	595	974	453
Male	4651	7043	3320
Unknown	2	2	0

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	3773	56	656	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.8 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER COASTAL Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH SHORE/ COAST GARIBALDI	10 years or more	246	189
	5 years or more	52	45
	<5 years	57	41
	<b>Total HSDA:</b>	<b>355</b>	<b>275</b>
RICHMOND	10 years or more	124	97
	5 years or more	36	26
	<5 years	50	44
	<b>Total HSDA:</b>	<b>210</b>	<b>167</b>
VANCOUVER	10 years or more	3301	2282
	5 years or more	767	545
	<5 years	615	504
	<b>Total HSDA:</b>	<b>4683</b>	<b>3331</b>
<b>Total HA:</b>		<b>5248</b>	<b>3773</b>

Treatment Duration	Alive	Currently treated with ARVs
10 years or more	3671	2568
5 years or more	855	616
<5 years	722	589
<b>Total HA:</b>	<b>5248</b>	<b>3773</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.9 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER COASTAL Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH SHORE/COAST GARIBALDI	189	415	37	50
RICHMOND	46	319	8	98
VANCOUVER	698	11810	229	5475
<b>Total:</b>	<b>933</b>	<b>12544</b>	<b>274</b>	<b>5623</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH SHORE/COAST GARIBALDI	*
RICHMOND	*
VANCOUVER	*
<b>Total:</b>	<b>66</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.10 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
VANCOUVER ISLAND Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>357</b>	<b>525</b>
NORTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>130</b>	<b>183</b>
SOUTH VANCOUVER ISLAND	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>		<b>818</b>	<b>1174</b>
<b>Total HA:</b>		<b>1305</b>	<b>1882</b>	<b>999</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	6	6	6
	20-34	108	117	69
	35-49	307	348	238
	50+	884	1411	686
<b>Total HA:</b>		<b>1305</b>	<b>1882</b>	<b>999</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	219	321	168
Male	1086	1561	831

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	999	56	610	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.11 Distribution of Participants in BC-CfE Registries by Treatment Duration VANCOUVER ISLAND Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
CENTRAL VANCOUVER ISLAND	10 years or more	227	185
	5 years or more	69	47
	<5 years	61	52
	<b>Total HSDA:</b>	<b>357</b>	<b>284</b>
NORTH VANCOUVER ISLAND	10 years or more	95	73
	5 years or more	23	19
	<5 years	12	10
	<b>Total HSDA:</b>	<b>130</b>	<b>102</b>
SOUTH VANCOUVER ISLAND	10 years or more	508	372
	5 years or more	161	122
	<5 years	149	119
	<b>Total HSDA:</b>	<b>818</b>	<b>613</b>
<b>Total HA:</b>		<b>1305</b>	<b>999</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	830	630
	5 years or more	253	188
	<5 years	222	181
<b>Total HA:</b>		<b>1305</b>	<b>999</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation







**4.12 Distribution of ARV Prescribers in BC-CfE Registries  
VANCOUVER ISLAND Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
CENTRAL VANCOUVER ISLAND	205	936	68	173
NORTH VANCOUVER ISLAND	161	286	39	71
SOUTH VANCOUVER ISLAND	228	1962	39	589
<b>Total:</b>	<b>594</b>	<b>3184</b>	<b>146</b>	<b>833</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
CENTRAL VANCOUVER ISLAND	107
NORTH VANCOUVER ISLAND	46
SOUTH VANCOUVER ISLAND	124
<b>Total:</b>	<b>277</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





**4.13 Distribution of Participants in BC-CfE Registries by Age and Sex at Birth  
NORTHERN Health Authority**

HSDA	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
NORTH EAST	20-34	8	8	*
	35-49	17	20	*
	50+	30	39	*
	<b>Total HSDA:</b>	<b>55</b>	<b>67</b>	<b>31</b>
NORTH WEST	20-34	*	5	*
	35-49	*	38	*
	50+	*	80	*
	<b>Total HSDA:</b>	<b>75</b>	<b>123</b>	<b>55</b>
NORTHERN INTERIOR	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
	<b>Total HSDA:</b>	<b>199</b>	<b>299</b>	<b>145</b>
<b>Total HA:</b>		<b>329</b>	<b>489</b>	<b>231</b>

	Age Group	Alive	Ever treated with ARVs	Currently treated with ARVs
	0-19	*	*	*
	20-34	*	*	*
	35-49	*	*	*
	50+	*	*	*
<b>Total HA:</b>		<b>329</b>	<b>489</b>	<b>231</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Female	114	175	79
Male	215	314	152

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total HA:</b>	231	53	555	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





**4.14 Distribution of Participants in BC-CfE Registries by Treatment Duration  
NORTHERN Health Authority**

HSDA	Treatment Duration	Alive	Currently treated with ARVs
NORTH EAST	10 years or more	31	*
	5 years or more	6	*
	<5 years	18	*
	<b>Total HSDA:</b>	<b>55</b>	<b>31</b>
NORTH WEST	10 years or more	53	37
	5 years or more	10	8
	<5 years	12	10
	<b>Total HSDA:</b>	<b>75</b>	<b>55</b>
NORTHERN INTERIOR	10 years or more	110	82
	5 years or more	53	36
	<5 years	36	27
	<b>Total HSDA:</b>	<b>199</b>	<b>145</b>
<b>Total HA:</b>		<b>329</b>	<b>231</b>

	Treatment Duration	Alive	Currently treated with ARVs
	10 years or more	194	133
	5 years or more	69	46
	<5 years	66	52
<b>Total HA:</b>		<b>329</b>	<b>231</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Treatment Duration** defined as number of years since ARV initiation





**4.15 Distribution of ARV Prescribers in BC-CfE Registries  
NORTHERN Health Authority**

HSDA of Prescriber Residency	# of Prescribers ever prescribed ARVs	# of Patients ever treated by Prescribers	# of Prescribers currently prescribing ARVs	# of Patients currently treated by Prescribers
NORTH EAST	39	51	6	8
NORTH WEST	88	188	15	43
NORTHERN INTERIOR	123	506	22	192
<b>Total:</b>	<b>250</b>	<b>745</b>	<b>43</b>	<b>243</b>

HSDA of Patient Residency	# of Patients seeking Prescriber's care out of HA
NORTH EAST	7
NORTH WEST	21
NORTHERN INTERIOR	15
<b>Total:</b>	<b>43</b>

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently prescribing/treated** defined as prescribing/being treated in the previous 6 months

**# of Patients seeking Prescriber out of HA** is defined as patients residing in specified HSDA, but their follow-up prescriber(s) reside in another HA





### 4.16 Distribution of Indigenous Participants in BC-CfE Registries by Health Service Delivery Area and Sex at Birth

HA	HSDA	Alive	Ever treated with ARVs	Currently treated with ARVs
INTERIOR	EAST KOOTENAY	*	10	*
	KOOTENAY BOUNDARY	*	9	*
	OKANAGAN	*	51	*
	THOMPSON/CARIBOO/SHUSWAP	*	53	*
	<b>Total HA:</b>	<b>68</b>	<b>123</b>	<b>50</b>
FRASER	FRASER EAST	36	52	28
	FRASER NORTH	51	94	39
	FRASER SOUTH	80	118	53
	<b>Total HA:</b>	<b>167</b>	<b>264</b>	<b>120</b>
VANCOUVER COASTAL	NORTH SHORE/COAST GARIBALDI	27	54	26
	RICHMOND	6	11	5
	VANCOUVER	447	912	371
	<b>Total HA:</b>	<b>480</b>	<b>977</b>	<b>402</b>
VANCOUVER ISLAND	CENTRAL VANCOUVER ISLAND	48	83	39
	NORTH VANCOUVER ISLAND	15	29	10
	SOUTH VANCOUVER ISLAND	49	97	37
	<b>Total HA:</b>	<b>112</b>	<b>209</b>	<b>86</b>
NORTHERN	NORTH EAST	11	15	6
	NORTH WEST	34	70	25
	NORTHERN INTERIOR	71	119	54
	<b>Total HA:</b>	<b>116</b>	<b>204</b>	<b>85</b>
<b>Total:</b>		<b>943</b>	<b>1777</b>	<b>743</b>

Sex at Birth	Alive	Ever treated with ARVs	Currently treated with ARVs
Male	602	1143	460
Female	341	634	283

Currently treated with ARVs	# of patients	Med Age	Med CD4	Med PVL
<b>Total:</b>	743	54	530	<40

\* Patient numbers > 0 and < 5 are suppressed for privacy purposes.

**Definitions:**

**Currently treated with ARVs** defined as being on ARV therapy in the specified month

**Med CD4 and PVL tests** defined as most recent tests (as of specified month)





## 5.1 Drug Names and Definitions

**Abacavir:** a NUCLEOSIDE ANALOG from ViiV Healthcare.

**Active:** persons in the HIV/AIDS Drug Treatment program that are prescribed one or more drugs in this current month

**Antiretroviral:** a substance that stops or suppresses the activity of a retrovirus, such as HIV. NUCLEOSIDE ANALOGS and PROTEASE INHIBITORS are examples of antiretroviral drugs.

**Atazanavir (Reyataz):** a PROTEASE INHIBITOR from Bristol-Myers Squibb.

**Atovaquone (Mepron):** a medication used to treat pneumocystis carinii pneumonia and, in some cases, toxoplasmosis.

**Atripla:** the Bristol-Myers Squibb and Gilead trade name for a tablet containing EFAVIRENZ, TENOFOVIR DF and EMTRICITABINE.

**Azithromycin (Zithromax):** an antibiotic used for the prevention of mycobacterium avium complex (MAC) in people with advanced HIV infection.

**Bictegravir:** an INTEGRASE INHIBITOR from Gilead Sciences.

**Boosted PI:** a PI and a small (400 mg or less, total daily dose) additional dose or RITONAVIR. The addition of RITONAVIR inhibits metabolism of other PIs and improves their exposure. This may allow for decreased dosing frequency or pill burden and may improve adherence and antiretroviral activity.

**Cabenuva:** the ViiV Healthcare trade name for an injectable formulation containing CABOTEGRAVIR and RILPIVIRINE.

**Cabotegravir:** an INTEGRASE INHIBITOR.

**CD4 Cell Count:** the most commonly used marker for assessing the state of the immune system. As CD4 cell count declines, the risk of developing opportunistic infections increases. Normal CD4 cell counts are greater than 800 per cubic millimeter of blood.

**Chemokine Receptor Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV entry by blocking the binding site of co-receptors, such as CCR5 or CXCR4.

**Clarithromycin (Biaxin):** an antibiotic used for the treatment of mycobacterium avium complex (MAC). It is also used for preventing MAC in those with advanced HIV infection.

**Cobicistat:** a pharmacokinetic enhancer (“booster”) given with other antiretrovirals to improve drug exposure. Cobicistat has no anti-HIV activity. It is currently available as a component of STRIBILD, GENVOYA and PREZCOBIX.

**Combination Therapy:** initial combination therapy for HIV contains at least three ANTIRETROVIRALS.

**Complera:** the Gilead trade name for a tablet containing EMTRICITABINE, RILPIVIRINE and TENOFOVIR DF.

**Darunavir (Prezista):** a PROTEASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**Deceased:** persons enrolled in the HIV/AIDS Drug Treatment program that died in this time period.

**Descovy:** the Gilead trade name for a tablet containing EMTRICITABINE and TENOFOVIR AF.





## Monthly Report

**Didanosine (Videx):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Dolutegravir (Tivicay):** an INTEGRASE INHIBITOR from ViiV Healthcare.

**Doravirine:** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Merck.

**Efavirenz (Sustiva, Auro efavirenz):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Bristol-Myers Squibb.

**Elvitegravir:** an INTEGRASE INHIBITOR from Gilead Sciences. It is currently available as a component of STRIBILD.

**Emtricitabine:** a NUCLEOSIDE ANALOG from Gilead Sciences. It is currently available as a component of TRUVADA and other combinations.

**Enfuvirtide (Fuzeon):** a FUSION INHIBITOR from Hoffman-La Roche that targets the gp41 protein on the surface of HIV. It is administered as a subcutaneous injection.

**Entry Inhibitor:** a drug that inhibits the entry of HIV into cells. Entry inhibitors include FUSION INHIBITORS, CHEMOKINE RECEPTOR INHIBITORS, and attachment inhibitors.

**Etravirine (Intence):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR from Janssen that has activity against HIV in treatment-experienced patients.

**First started program:** a person prescribed their first regimen ever in the HIV/AIDS drug treatment program.

**Fosamprenavir (Telzir):** a PROTEASE INHIBITOR from ViiV Healthcare. Fosamprenavir is a PRODRUG of AMPRENAVIR.

**Fostemsavir:** an ATTACHMENT INHIBITOR from ViiV Healthcare. Fostemsavir is a PRODRUG of TEMSAVIR.

**Fusion Inhibitor:** a type of ENTRY INHIBITOR designed to prevent HIV from fusing with and thereby infecting CD4 cells.

**Genvoya:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICSTAT, EMTRICITABINE and TENOFOVIR AF.

**Health Authority:** refers to the five (Interior, Fraser, Northern, Vancouver Coastal, Vancouver Island) health authorities created by the BC Ministry of Health.

**Inactive:** persons no longer dispensed drugs through the HIV/AIDS Drug Treatment program this current month.

**Integrase Inhibitor:** a drug that blocks integrase, a protein that HIV needs to enter cells and produce copies of itself, from working.

**Kivexa:** the ViiV Healthcare's trade name for a tablet containing both ABACAVIR and LAMIVUDINE.

**Lamivudine:** a NUCLEOSIDE ANALOG from ViiV Healthcare with activity against HIV and hepatitis B.

**Lopinavir (Kaletra):** a PROTEASE INHIBITOR from Abbott Laboratories. Kaletra is a combination of lopinavir and a low dose of RITONAVIR, a drug that improves blood levels of lopinavir.

**Maraviroc (Celsentri):** a CHEMOKINE RECEPTOR INHIBITOR from ViiV Healthcare that inhibits HIV entry by blocking the binding site of the CCR5 co-receptor.

**Median (MED) age:** median age of participants in the HIV/AIDS Drug Treatment program in that time period.





## Monthly Report

**MDRT:** see MULTIPLE DRUG RESCUE THERAPY

**Moved out of BC:** a person in the HIV/AIDS Drug Treatment program that is no longer in the program, because they moved out of BC in this time period.

**Multiple Drug Rescue Therapy (MDRT or Mega-HAART):** the use of five or more antiretrovirals to treat HIV, typically some or all of which have been used previously by the individual.

**Nelfinavir (Viracept):** a PROTEASE INHIBITOR from ViiV Healthcare.

**Net change:** the net increase or decrease in persons enrolled in the HIV/AIDS Drug Treatment Program from the previous time period.

**Nevirapine (Viramune):** a NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Boehringer Ingelheim.

**NNRTI:** see NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR.

**NNRTI / no PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including an NNRTI, but no PIs.

**Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI):** a member of a class of compounds, including DELAVIRDINE, NEVIRAPINE, EFAVIRENZ and ETRAVIRINE that acts to directly combine with and block the action of HIV's reverse transcriptase enzyme.

**N(t)RTI:** a category of drug encompassing both NUCLEOSIDE ANALOG and NUCLEOTIDE ANALOG

**Nucleoside Analog (Nucleoside Analog Reverse Transcriptase Inhibitor, NRTI):** a type of ANTIVIRAL drug whose structure constitutes a defective version of a natural nucleoside. Nucleoside analogs may take the place of the natural nucleosides, blocking the completion of a viral DNA chain during infection of a new cell by HIV. The HIV enzyme reverse transcriptase is more likely to incorporate nucleoside analogs into the DNA it is constructing than is the DNA polymerase that cells normally use for DNA construction.

**Nucleotide Analog:** ANTIVIRAL compounds that function exactly like NUCLEOSIDE ANALOGS but are pre-activated through the addition of a phosphate group during their synthesis. This phosphorylation is supposed to enhance the drug levels and activity achieved within cells.

**Odefsey:** the Gilead trade name for a tablet containing RILPIVIRINE, EMTRICITABINE and TENOFOVIR AF.

**One or more PI:** a combination therapy regimen of four or fewer antiretroviral drugs, including one unboosted PI or 2 or more PIs with or without a small (400 mg or less, total daily dose) additional dose of RITONAVIR.

**Other:** an antiretroviral regimen in the HIV/AIDS Drug Treatment program other than NNRTI/no PI, boosted PI, 1 or more PIs or MDRT-based regimens (eg. Triple Nucleoside regimens).

**Pentamidine:** an antiprotozoal drug used in aerosol form as a preventative against pneumocystis carinii pneumonia (PCP).

**PI:** see PROTEASE INHIBITOR.

**Prezcobix:** the Janssen trade name for a tablet containing DARUNAVIR and COBICISTAT.

**Prodrug:** a compound that is converted within the body into the active form that has medical effects.

**Protease Inhibitor:** a drug that binds to and blocks HIV protease from working, thus preventing the production of new functional viral particles.







## Monthly Report

**Raltegravir (Isentress):** an INTEGRASE INHIBITOR from Merck.

**Restarted/ changed therapy (Tx):** a person in the HIV/AIDS Drug Treatment program that was either CURRENTLY OFF THERAPY and now has been prescribed a new regimen or a person who has changed regimens.

**Rifabutin (Mycobutin):** an oral drug used to prevent mycobacterium avium complex (MAC) in people with advanced HIV infection. Rifabutin is also used in combination with other drugs for the treatment of active MAC infections.

**Rilpivirine (Edurant):** a NON-NUCELOSIDE REVERSE TRANSCRIPTASE INHIBITOR (NNRTI) from Janssen.

**Ritonavir (Norvir):** a PROTEASE INHIBITOR from Abbott. Ritonavir is commonly used to inhibit the liver enzyme metabolism of other protease inhibitors and improve their blood exposure (“booster”).

**Stavudine (Zerit):** a NUCLEOSIDE ANALOG from Bristol-Myers Squibb.

**Stopped all therapies (Tx):** a person in the HIV/AIDS Drug Treatment program that stopped all therapies in this time period and is now CURRENTLY OFF THERAPY.

**Stribild:** the Gilead trade name for a tablet containing ELVITEGRAVIR, COBICISTAT, EMTRICITABINE and TENOFOVIR DF.

**Tenofovir alafenamide (Tenofovir AF, TAF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV. It is currently available as a component of DESCOVY and GENVOYA.

**Tenofovir disoproxil fumarate (Viread, Tenofovir DF, TDF):** a NUCLEOTIDE ANALOG from Gilead Sciences with activity against HIV and hepatitis B.

**Tipranavir (Aptivus):** a PROTEASE INHIBITOR from Boehringer Ingelheim that has activity against HIV in treatment-experienced patients.

**Triple Therapy:** the use of three drugs, most often a PROTEASE INHIBITOR or NON-NUCLEOSIDE ANALOG with two NUCLEOSIDE ANALOGS, in the treatment of HIV.

**Triumeq:** the ViiV Healthcare’s trade name for a tablet containing DOLUTEGRAVIR, ABACAVIR and LAMIVUDINE.

**Trizivir:** the ViiV Healthcare’s trade name for a tablet containing ABACAVIR, ZIDOVUDINE and LAMIVUDINE.

**Truvada:** the Gilead trade name for a tablet containing TENOFOVIR DF and EMTRICITABINE.

**Valganciclovir:** an antiviral drug used to treat cytomegalovirus (CMV) retinitis.

**Viral Load:** the amount of HIV RNA per unit of blood plasma. An indicator of virus concentration and reproduction rate. HIV viral load is employed as a measure of the success of antiretroviral therapy.

**Zidovudine (Retrovir):** a NUCLEOSIDE ANALOG from ViiV Healthcare. AZT is also approved for preventing maternal-fetal HIV transmission.

